## Attorney Docket No. 080411-000000US

U.S. DEPARTMENT OF COMMERCE United States Patent and Trademark Office

PTO-1595 (Rev. 06/04)	United States Patent and Hedshites		
No. 0651-0027 (exp. 6/30/2000)	COVER SHEET		
ロッチにいて	S ONLY		
	the attached documents or the new address(es) below.		
To the Director of the U.S. Patent and Trademark Office: Please to	2. Name and address of receiving party(ies)		
Name of conveying party(les)/Execution buto(-)	Name: bioMD LIMITED		
AFRA DESIGN PTY. LIMITED	Internal Address:		
	IIII III III III III III III III III I		
	Street Address: Level 11		
(ecution Date(s) June 24, 2004	225 St George's Terrace		
ditional name(s) of conveying party(ies) attached? Yes No	225 St George's Tomas		
Nature of conveyance:	City: Perth		
Morger			
Assignment — Change of Name	State: Western Australia		
Security Agreement	Zip: 6000		
Government Interest Assignment	Country: Australia Zip. 6000		
Executive Order 9424, Confirmatory License			
Executive Order 9424, Communities of Executive Order 9424, Communities of Executive Parameters of Executive Order 9424, Communities of Executive Order 942	additional name(s) & address(es) attached? Yes No		
015262, Frame 0641	Additional name(s) & address(		
4. Application or patent number(s):	is document is being lined together.		
4. Application No (s)	B. Patent No.(s)		
A. Patent Application No.(s) PCT/AU03/00617 (US National Phase			
Additional numbers a	attached? Yes No		
5. Name and address to whom correspondence	6. Total number of applications and person		
5. Name and address to whom concerning document should be mailed:	involved:		
	7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00		
Name: J. Georg Seka	Authorized to be charged by credit card		
Internal Address:	Authorized to be charged to deposit account		
TOWNSEND AND TOWNSEND AND CREW LLF	-   [] Englosed		
Street Address: Two Embarcadero Center,	None required (government interest not affecting title)		
Eighth Floor	8. Payment Information		
City: San Francisco	Credit Card Last 4 numbers		
State: California Zip: 94111-3834	- Expiration Date		
Phone Number: (415) 576-0200	b. Deposit Account Number 20-1430		
	Authorized User Name Townsend and		
Fax Number: (415) 576-0300	Townsend and Crew L		
Email Address: jgs@townsend.com	January 4, 2005		
9. Signature: Signature	Date		
- O.g	Total number of pages including cover sheet, attachments, and documents:		
J. Georg Seka  Name of Person Signing Atty. Reg.	No. 24,491 sheet, attachments, and coosins with the sheet should be faxed to (703) 306-5995, or mailed to:		

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or malled to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandrie, VA 22313-1450

60386414 vl

**PATENT REEL: 015529 FRAME: 0776** 

## 700124014

1,001210	911000000		
	Attorney Docket No. 080411-000000US  U.S. DEPARTMENT OF COMMERCE		
PTO-1595 (Rev. 06/04)	U.S. DEPARTMENT OF TRANSPORTED United States Patent and Trademark Office		
RECORDATION FO	ORN COVER SHEET		
PATEN	ITS ONLY		
To the Director of the U.S. Patent and Trademark Office: Ples	are record the attached documents or the new address(se) below.		
Name of conveying party(ies)/Execution Date(s	): 2. Name and address of receiving party(les) Name: bloMD LIMITED		
AFRA DESIGN PTY. LIMITED	142(110)		
VI I A DESIGNATION	Internal Address:		
	. 144		
ecution Date(s) June 24, 2004	Street Address: Level 11		
ditional name(s) of conveying party(ies) stracted? Yes	No 225 St George's Terrace		
Nature of conveyence:	City: Perth		
Assignment Merger  Security Agreement Change of Name	e State: Western Australia		
Tabourd value			
Government Interest Assignment	Country: Australia Zip: 6000		
Executive Order 9424, Confirmatory License	Additional name(s) & address(es) attached? Ye4 No		
Other	This document is being filed together with a new application		
Application of between the contract of the con	B. Patent No.(3)		
A. Patent Application No.(s)	D. Patericitation		
PCT/AU03/00617 (US Netional Phase			
Application No. 10/494,404)	ens attached? Yes No		
<ol> <li>Name and address to whom correspondence concerning document should be mailed:</li> </ol>	involved:		
concerning document arrange as a second	7. Total fee (97 CFR 1.21(h) & 3.41) \$ 40.00		
Name: J. Georg Seka	Authorized to be charged by credit card		
Internal Address:	l ==3 denosit account		
TOWNSEND AND TOWNSEND AND CREW L	Fortneed		
Street Address: Two Embarcadero Center,	None required (government interest not affecting title		
Eighth Floor	2 Payment information		
City: San Francisco	- Condit Cord 1 ast 4 numbers		
State: California Zip: 94111-383	Expiration Date		
Phone Number: (415) 576-0200	b. Deposit Account Number 20-1430		
Fax Number: (415) 576-0300	Authorized User Name_Townsend and		
Email Address:  gs@townsend.com /	Townsend and Crew L		
	October 18, 2004		
9. Signature:Signature	Date Date		
J. Georg Seka	Total number of pages arcidos globas		
Name of Person Signing Atty. Reg	g. No. 24,491		

Documents to be recorded (including cover sheet) should be faxed to (703) 364-595, or mailed to:
Mail Step Assignment Recordation Services, Director of the USPTO, P.O.Box 1460, Abstractic, VA 22513-1450

**6**0335478 Yl

**REEL: 015529 FRAME: 0777** 

I, William George Bennett herewith certify that I have sighted the original Assignment Deed dated 24 June 2004 between Afra Design Pty. Limited and bioMD Limited and I confirm that attached hereto is a true copy thereof.

Dated this 19th day of July 2004

William George Bennett
Registered Patent Attorney

PATENT REEL: 015529 FRAME: 0778 Dated

24th Tune

2004

# ASSIGNMENT OF INTELLECTUAL PROPERTY

**Parties** 

AFRA DESIGN PTY LTD ABN 21 001 265 425

**bioMD LIMITED** ABN 35 088 221 078

PATENT

**REEL: 015529 FRAME: 0779** 

#### **DEED** made

**PARTIES** 

AFRA DESIGN PTY LTD ABN 21 001 265 425 of 11 Patterson Street, Tahmoor, NSW, 2573 ("Afra")

AND

bioMD LIMITED ABN 35 088 221 078 of Level 11, 225 St George's Terrace, Perth, WA, 6000 ("bioMD")

#### INTRODUCTION

- A. Afra owns the Syringe Patents which relate to the Inventions.
- B. Afra and bioMD entered into a Patent Licence Agreement in relation to the Syringe Patents on 1 October 2003, under which Afra agreed to assign the Syringe Patents on payment by bioMD of the Purchase Price.
- C. bioMD has paid the Purchase Price to Afra, and Afra wishes to assign to bioMD and bioMD wishes to accept the Syringe Patents on the terms and conditions of this Deed.

#### IT IS AGREED

- 1. Definitions
- 1.1 In this Deed:
  - (1) "Agreement" means the Patent Licence Agreement between the parties dated 1 October 2003;
  - (2) "Deed" means this document, including any schedule or annexure to it; and
  - (3) "Effective Date" means the date on which bioMD paid the Balance to Afra pursuant to clause 4.4 of the Agreement.

"Syringe Patents" means the patents and patent applications relating to the Inventions filed by or on behalf of Afra as set out in the Schedule, and includes: and any applications derived Reseptor, and includes:

- (a) any additional patents or patent applications filed in Australia, Japan, the USA or the European Union in relation to the Inventions; and
- (b) the Confidential Information and Materials; and
- (c) all other IPR owned by Afra relating to the Inventions.

Page 1 2402915/06/2004

- 1.2 In this Deed:
  - (1) capitalised terms have the meaning given to them in the Agreement; and
    - (2) "including" and similar expressions are not words of limitation.
- 2. Assignment and Transfer
- 2.1 In consideration of payment of the Purchase Price (receipt of which is acknowledged), Afra assigns to bioMD all its right title and interest in the Syringe Patents and the Materials, including the benefit of any prior claims in relation to the Syringe Patents including infringement of it, with effect on the Effective Date.
- 2.2 Afra must deliver up to bioMD within 3 Business Days after the Effective Date all Materials and all certifications of title, papers, plans, reports and items in relation to all the Syringe Patents which are not already in the possession of bioMD.
- 2.3 For a period of two (2) years from the Effective Date, bioMD may request Afra to provide consultancy services on the same terms as set out in clause 7 of the agreement except that the reference to "licences/licence" in clause 7.5 shall be read as a reference to "assigns/assignment".
- 3. Warranties and Indemnities
- 3.1 In addition to the warranties given by Afra under clause 8 of the Agreement, Afra warrants to bioMD that:
  - (1) without limiting Afra's rights under the Agreement and this Deed, bioMD will have and enjoy quiet possession of the Intellectual Property uninterrupted by Afra or any person claiming under Afra; and
  - (2) Afra has not entered into any agreement or arrangement involving the sale, mortgage, pledge, granting of options or any other rights over Afra's rights, title and interest in the Syringe Patents and Materials;
- 3.2 bioMD indemnifies and at all times holds harmless Afra, its Related Bodies Corporate, officers, agents and employees against any losses, costs, actions, claims, demands, expenses, judgments, court orders or other liabilities arising directly or indirectly out of or in connection with bioMD's use of and ownership of the Syringe Patents and Materials after the Effective Date.
- 3.3 bioMD acknowledges that Afra has received financial and other assistance from Victoria Park Investments and Nepean Engineering (both of Narellan, NSW), and that information relating to the arrangement has been provided to bioMD.
- 4. Confidentiality
- 4.1 Afra must from the date of this Deed:

Page 2 2402915/06/2004

- maintain and take all steps necessary to maintain all Confidential Information in strictest confidence;
- (2) take all precautions necessary to prevent accidental disclosure of any of the Confidential Information;
- not disclose any of the Confidential Information to any person;
- (4) not disclose the existence of the Confidential Information to any person; and
- (5) not use the Confidential Information in any way, unless otherwise agreed between the parties in writing.
- 4.2 Afra's obligations and undertakings under this clause continue indefinitely and are not diminished or terminated by the completion or termination for any reason of this Deed.

#### 5. General

- 5.1 Time is of the essence of this Deed.
- 5.2 Each party must promptly at its own cost do all things (including executing and if necessary delivering all documents) necessary or desirable to give full effect to this Deed.
- 5.3 If anything in this Deed is unenforceable, illegal or void then it is severed and the rest of this Deed remains in force.
- 5.4 This Deed and the Agreement:
  - is the entire agreement and understanding between the parties on everything connected with the subject matter of this Deed; and
  - (2) supersedes any prior agreement or understanding on anything connected with that subject matter.
- 5.5 Any fees, costs and expenses incurred in connection with enabling bioMD to be registered at the sole owner of the Syringe Patents must be borne and paid by bioMD.
- 5.6 Each party must pay its own costs and outlays connected with the negotiation, preparation and execution of this Deed.
- 5.7 The law of New South Wales governs this Deed.
- 5.8 The parties submit to the non-exclusive jurisdiction of the courts in New South Wales and of the Commonwealth of Australia.

#### Schedule 1

### The Syringe Patents

Country	Number	Filing Date	Title
Australia	PQ5249	27 Jan 2000	A pre-filled safety syringe
Australia	PQ8484	3 Jul 2000	A pre-filled safety syringe
International	PCT/AU00/01027	30 Aug 2000	A pre-filled safety syringe
Australia	2000268103	30 Aug 2000	A pre-filled safety syringe
Europe	00955961.8	30 Aug 2000	A pre-filled safety syringe
Japan	2001-554741	30 Aug 2000	A pre-filled safety syringe
USA	10/206,868	30 Aug 2000	A pre-filled safety syringe
Australia	PR6575	26 Jul 2001	Safety Syringe
International	PCT/AU01/01391	30 Oct 2001	Safety Syringe
Australia	2002950988	26 Aug 2002	Needle Assembly
International	PCT/AU03/00617	22 May 2003	Needle Assembly
Australia	2003902924	14 Jun 2003	Dental Syringe

EXECUTED as a deed.

Executed by **AFRA DESIGN PTY LTD**ABN 21 001 265 425 in accordance
with section 127 of the *Corporations*Act 2001:

Director/Company Secretary

Name of Director/Company Secretary (BLOCK LETTERS)

Director formula

FRANK POPOUS & 9
Name of Director
(BLOCK LETTERS)

Executed by **bioMD LIMITED**ABN 35 088 221 078 in accordance with section 127 of the Corporations Act 2001:

Director/Company Secretary

Name of Director/Company Secretary (BLOCK LETTERS)

Director

Name of Director

(BLOCK LETTERS)

**RECORDED: 01/04/2005**